Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.

@article{Wallentin2003OralXF,
  title={Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.},
  author={Lars Wallentin and Robert G. Wilcox and William D. Weaver and H{\aa}kan U. Emanuelsson and Andrew Goodvin and Per Olof Nystr{\"o}m and Anders Bylock},
  journal={Lancet},
  year={2003},
  volume={362 9386},
  pages={789-97}
}
BACKGROUND Despite important advances in treatment, the risk of recurrent ischaemic events is high both early and late after an acute coronary syndrome. We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction. METHODS In this placebo-controlled, double-blind, multicentre, multinational dose-guiding study we assessed 1883 patients who had had… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 110 extracted citations

Similar Papers

Loading similar papers…